无论是甲福明还是乌尔索多西可酸都不能有效治疗COVID-19的后急性后果:一项随机临床试验
So Yun Lim1, Jacob Lee2, Euijin Chang1
1Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea (S.Y.L., E.C., J.-S.K., C.Y.J., H.M.J., S.K.).
两周的甲福明或ursodeoxycholic acid (UDCA) 疗程并没有显著改善SARS-CoV-2感染 (PASC) 后急性继发症的成年人的康复. 为了有效的长期COVID治疗,需要进一步的研究.
科学领域:
- 临床医学 临床医学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- SARS-CoV-2 感染 (PASC) 或长期COVID的后急性后续症状,在没有确立的治疗方法的情况下,构成了重大的公共卫生挑战.
- 目前对PASC症状的治疗选择有限,需要对新型干预措施进行研究.
研究的目的:
- 评估甲福明和ursodeoxycholic acid (UDCA) 在减轻成人PASC症状方面的疗效.
- 为了确定这些药物是否可以提高长期COVID患者的康复率.
主要方法:
- 进行了一项双盲,安慰剂控制,随机的临床试验,涉及396名患有PASC的成年人.
- 参与者接受了口服甲胺,UDCA或安慰剂14天,恢复被定义为8周后PASC指数得分低于12的恢复.
主要成果:
- 8周后的康复率在各组中相似:63.6%与甲福林,68.2%与UDCA,68.2%与安慰剂.
- 在甲福林,UDCA和安慰剂组之间没有观察到PASC症状改善的统计学上显著差异.
结论:
- 短期 (14天) 的甲福明或UDCA疗程在改善PASC的恢复方面没有显著的有效性.
- 这些发现表明,在测试条件下,甲胺和UDCA不是长期COVID恢复的有效治疗方法.
更多相关视频
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Ulcerative Colitis in IBD
Oral Hypoglycemic Agents: Biguanides and Glitazones
